Genmab stock slips as revenue rose 5.48% to $1.18 billion
Published on 08/31/2026 at 16:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Genmab stock (DK0010272202) edged lower in Stockholm as the latest quoted session showed 2,156.00 SEK in New York terms, 33.23 USD, and a market value of 33.18 billion SEK.
The same snapshot put the share at 2,156.00 SEK, down 0.6%, with 1,518,714 shares traded and a five-day move of -0.21%.
Quarterly numbers matter
Genmab reported revenue of $1.18 billion for the quarter ended June 30, 2026, up 5.48% from $1.11 billion a year earlier, and EPS of $0.16 versus $0.08 in the prior-year quarter.
That mix points to a business still growing, but at a pace investors will compare against the larger move in earnings per share, which doubled year over year.
Peer context
The stock sat at 33.18 billion SEK in market value, while the quoted close of 96.76 SEK and average target of 96.84 SEK in the same market snapshot left little distance between the two figures.
For investors, that makes the next report and any change in the revenue-to-earnings path more important than a broad market swing.
Genmab's core drug base
Genmab's antibody portfolio remains led by Darzalex, a key therapy in its oncology franchise and a central driver of commercial scale.
The product mix matters because Genmab's growth has to carry both revenue expansion and profit conversion at the same time.
Stock level to watch
Genmab shares traded at 33.23 USD in the latest quoted session, and the market value stood at 33.18 billion SEK.
Fact box
Company: Genmab A/S
ISIN: DK0010272202
Ticker: GMAB
Exchange: Nasdaq Copenhagen
Price (as of August 31, 2026): 33.23 USD
Market cap: 33.18 billion SEK
Sector / Industry: Health Care / Biotechnology
Index membership: OMX Copenhagen 25
Next earnings date: October 29, 2026
More on Genmab stock
Darzalex remains the company's most important commercial medicine and the clearest reference point for Genmab's revenue base.
